ESG > Social

Accessible to all

 

To address unmet medical needs of underserved populations and to prepare for future pandemics, we work with every part of the world to advance the discovery, development, scale-up, and manufacturing of vaccines and therapeutics.

We aim to make RNA products more accessible to low- and middle-income countries and believe that local needs are best addressed when we partner locally from the very beginning of the product research and development process.

In our plant health development process, we are committed to engaging with local agencies, agricultural partners, and academic institutions to create solutions to protect regional crops from relevant pests.

We are establishing a global network of partnerships and workforce development to advance research and manufacturing of effective and selective solutions targeting local pests.

Global partnerships

We actively seek to partner with local companies in Africa, Asia, and Latin America to advance equitable access to messenger RNA vaccines and therapeutics targeting regionally prevalent diseases.

These partnerships aim to develop skills and capabilities to research, develop, make, and commercialize messenger RNA products.

Committed to representation at all levels

We continuously work to improve our representation of gender, race, and ethnicity at all levels, including our board, VP, and executive levels.

Full-time employees

GreenLight's commitment to diversity has risen year over year even as our employee base grows.
45% Female

As of March 2022, 45% of our full-time employees self-identify as female.

45% Non-Caucasian

45% of our full time employees identifies as a non-Caucasian racial or ethnic group*.

*Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian or Native Hawaiian, other Pacific Islander, or two or more races or ethnic groups.

Executive team & Senior Vice Presidents

Almost half are women and minorities
50% Female

50% of our Executive team members and Senior Vice Presidents are female.

40% Non-caucasian

40% of our Executive team identifies as a non-Caucasian racial or ethnic group*.

*Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian or Native Hawaiian, other Pacific Islander, or two or more races or ethnic groups.

Board of Directors

GreenLight’s board is twice as diverse as the S&P average.
42% is diverse

42% of our board is racially and ethnically diverse.

Diverse board

33% of our non-executive board members are women, and 71% represent the LGBTQ+ and non-Caucasian communities.

*Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian or Native Hawaiian, other Pacific Islander, or two or more races or ethnic groups.

C-Suite

Women in the C-suite at GreenLight are almost double the industry average.
40% Female

Women make up 40% of the C-suite at GreenLight compared to the industry average of 24%.

Source: State of Racial, Ethnic & Gender Diversity, MassBio, Nov 2021.

Research and Scientist positions

STEM diversity at GreenLight exceeds the industry average.
46% Female

46% of our employees in Research and Scientist positions are female, when women make up only 28% of the STEM workforce.

Source: State of Racial, Ethnic & Gender Diversity, MassBio, Nov 2021.

Corporate Social Responsibility

Our culture is built on care, transparency, employee ownership, and a deep, humble respect for science.

The growth in representation of female and racial and ethnic minority employees at GreenLight has outpaced our overall employee population growth; our employee base has increased 61% since March 2021, whereas there was a 66% and 80% increase in representation of women and ethnic and racial minorities, respectively.

We regularly measure and share with employees information about our gender pay gap and company statistics.

Our employee-run resources groups focus on common priorities and areas of interest, including the LGBTQ+ community, women, community service and fundraising, wellness, and equity, diversity & inclusion.